Category: Treatment
Prostacyclin could help the most severely affected Covid-19 patients in ICU
A research team headed by Prof. Pär Johansson from the Department of Clinical Immunology at Rigshospitalet has investigated whether treatment with prostacyclin can help patients by reducing damage to the endothelial cells, which lines the inside of all blood vessels. More...
USA: Hyenas test positive for Sars-Cov-2 in Colorado zoo
Two hyenas at the Denver Zoo have tested positive for the coronavirus, the first confirmed cases among the animals worldwide. More...
UK approves oral Covid drug Molnupiravir for use
UK Health and Social Care Secretary Sajid Javid said “Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for COVID-19. More...
The dangers of new oral Covid drug Molnupiravir
“The FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval. More...
1918 pandemic caused Long Covid like symptoms in survivors
“The influenza pandemic of 1918 was followed by another epidemic. More...
UK ONS: Natural infection by Covid provides a similar level of protection to two vaccine doses
UK Office of National Statistics: “Two vaccination doses provided a similar level of protection to previous natural infection during the Delta-dominant period”
Modelled risk ratios of testing positive for COVID-19 by COVID-19 vaccine exposure, when the Delta variant was dominant, UK, 17 May to 14 August 2021
- there was no evidence that the reduction in risk of infection from two doses of either vaccine differed from that of previous natural infection
- two doses (14 days or more previously) of Pfizer-BioNTech reduced the risk of testing positive by 73% (95% confidence interval: 70% to 76%) in the Delta period, compared with 80% (95% confidence interval: 74% to 85%) in the Alpha period
- two doses (14 days or more previously) of Oxford-AstraZeneca reduced the risk of testing positive by 62% (95% confidence interval: 58% to 66%) in the Delta period, compared with 76% (95% confidence interval: 62% to 85%) in the Alpha period
- the reduction in risk 14 days or more after second dose was significantly higher with Pfizer-BioNTech compared with Oxford-AstraZeneca
- the risk reduction from two doses of either vaccine was greater than from one dose (21 days or more previously)
UK ONS report: Coronavirus (COVID-19) Infection Survey Technical Article: Impact of vaccination on testing positive in the UK: October 2021
Israel: 150 children treated for long Covid in one clinic, hundreds more on waiting list
“What’s interesting, is that in some of the children, it really appears as a direct continuation of severe illness but in very many of the children, there is a severe illness, followed by a lull of several months and only then do the symptoms of long COVID begin,” says Ashkenazi-Hoffnung. More...
Corneal nerve fibre loss and increased dendritic cells in patients with long Covid
This study has quantified corneal sub-basal nerve plexus morphology and dendritic cell (DC) density in patients with and without long COVID.
Plant-based or pescatarian diets were associated with lower odds of moderate to severe COVID-19
There were 568 COVID-19 cases and 2316 controls. Among the 568 cases, 138 individuals had moderate-to-severe COVID-19 severity whereas 430 individuals had very mild to mild COVID-19 severity. More...
Thailand authorizes Covid vaccine injections under the skin
“One vaccine dose can be used for five intradermal injections,” a Thai doctor said. More...